Evaluate the Effect of Lifenol in Improving Bone Status in Postmenopausal Osteopenic Women

Inclusion Criteria: 1. Be able to give written informed consent; 2. Be 50 - 85 years of age; 3. Be a free-living postmenopausal (\> 1 year post menopause) woman; 4. Have a Body Mass Index (BMI) 18 - 32.0 kg/m²; 5. Present with a stable weight (+/- 3 kg) for at least the last three (3) months; 6. Be a non-smoker 7. Maintain existing food and physical activity patterns throughout the study period; 8. Present with osteopenia defined as a dual energy X-ray absorptiometry (DXA) T score comprised between -1 and -2.5; 9. Be willing to consume the investigational product daily for the duration of the study. Be able to give written Exclusion Criteria: 1. Are hypersensitive to any of the components of the investigational product; 2. Is currently involved in any other clinical trial or having participated in a trial within the preceding 60 days; 3. Has a diagnosis of osteoporosis (defined as a T score strictly inferior to -2.5); 4. Is currently a smoker; 5. Trying to lose weight for the last three (3) months (following a diet or exercise regimen designed for weight loss); 6. Recent (within 4 weeks) gastroenteritis or food borne illness; 7. Having taken antibiotics or laxatives during the preceding 2 months or anticipated consumption; 8. Currently taking (and during the past 3 months) any drug for osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate or denosumab); 9. Currently taking (and during the past 3 months) treatment with oestrogen or hormone therapy; 10. Currently taking (and during the past 3 months) treatment with oestrogen agonist or antagonist products (raloxifene or tamoxifene); 11. Currently taking any supplementation with isoflavones or foods fortified with isoflavones; 12. Currently taking (and during the past 4 weeks) any vitamin K supplementation. 13. Exhibiting excess alcohol consumption, defined as greater than 11 standard drinks per week for women or drug dependence, 14. Has a significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude supplement ingestion and/or assessment of safety and the study objectives; 15. Has a known organic disease, including an inflammatory bowel disease, a benign or malign tumour of intestine or colon and significant systemic disease; 16. Has a history of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, or carcinoma in situ with no significant progression over the past 2 years; 17. Has uncontrolled hypertension (systolic or diastolic blood pressure superior to 160 and 110 respectively). Subject on hypertension medication, must be on stable medication for 3 months; 18. Has uncontrolled hypothyroidism or hyperthyroidism; subject must be stable on medication for 3 months 19. Current illnesses which could interfere with the study (e.g. prolonged severe diarrhoea, regurgitation/severe, difficulty swallowing). 20. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.